COVID-19 Vaccine
A COVID-19 Vaccine is a vaccine for Covid-19 (designed to provide immunity against the SARS-CoV-2 virus).
- Context:
- It can (often) be an mRNA Vaccine that uses messenger RNA technology to stimulate an immune response.
- ...
- It can range from being an Original COVID-19 Vaccine to being a Future COVID-19 Vaccine.
- ...
- It can be a Protein Subunit Vaccine that contains protein fragments from SARS-CoV-2 to provoke immunity.
- It can be a Viral Vector Vaccine that uses a harmless virus to deliver SARS-CoV-2 genetic material, prompting an immune response.
- It can be administered as a single dose or multiple doses depending on factors such as age and health status.
- It can cause mild side effects, such as soreness at the injection site, fatigue, and fever, which typically subside within a few days.
- ...
- Example(s):
- a COVID-19 mRNA Vaccine such as:
- Moderna (mRNA-1273) Covid-19 Vaccine,
- Pfizer-BioNTech (MRNA) COVID-19 Vaccine,
- Moderna Spikevax COVID-19 Vaccine (updated for 2024-2025 variants),
- a COVID-19 Adenovirus Vector Vaccine such as:
- a COVID-19 Inactivated Virus Vaccine such as:
- a COVID-19 Subunit Vaccine such as:
- ...
- a COVID-19 mRNA Vaccine such as:
- Counter-Example(s):
- See: Covid-19 Vaccine Trial, COVID-19 Pandemic, World Health Organization (WHO), mRNA, Adenovirus, Subunit Vaccine, DNA Plasmid Vaccine.
References
2022
- (Wikipedia, 2022) ⇒ https://en.wikipedia.org/wiki/COVID-19_vaccine Retrieved:2022-3-27.
- A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 (COVID‑19).
Prior to the COVID‑19 pandemic, an established body of knowledge existed about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). This knowledge accelerated the development of various vaccine platforms during early 2020. The initial focus of SARS-CoV-2 vaccines was on preventing symptomatic, often severe illness. On 10 January 2020, the SARS-CoV-2 genetic sequence data was shared through GISAID, and by 19 March, the global pharmaceutical industry announced a major commitment to address COVID‑19. The COVID‑19 vaccines are widely credited for their role in reducing the severity and death caused by COVID‑19. Many countries have implemented phased distribution plans that prioritize those at highest risk of complications, such as the elderly, and those at high risk of exposure and transmission, such as healthcare workers. , 11.16billion doses of COVID‑19 vaccines have been administered worldwide based on official reports from national public health agencies. By December 2020, more than 10 billion vaccine doses had been preordered by countries, with about half of the doses purchased by high-income countries comprising 14% of the world's population.
- A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 (COVID‑19).
2021
- (Rosenblum et al., 2021) ⇒ Hannah G. Rosenblum, Stephen C. Hadler, Danielle Moulia, Tom T. Shimabukuro, John R. Su, Naomi K. Tepper, Kevin C. Ess et al. (2021). “Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and MRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021.” In: Morbidity and Mortality Weekly Report, 70(32).
- QUOTE: ... In December 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUAs) for Pfizer-BioNTech and Moderna COVID-19 vaccines, and in February 2021, FDA issued an EUA for the Janssen (Johnson & Johnson) COVID-19 vaccine. After each EUA, the Advisory Committee on Immunization Practices (ACIP) issued interim recommendations for vaccine use; currently Pfizer-BioNTech is authorized and recommended for persons aged ≥12 years and Moderna and Janssen for persons aged ≥18 years (1–3). Both Pfizer-BioNTech and Moderna vaccines, administered as 2-dose series, are mRNA-based COVID-19 vaccines, whereas the Janssen COVID-19 vaccine, administered as a single dose, is a recombinant replication-incompetent adenovirus-vector vaccine. ...
... One (myocarditis, cardiac inflammation) has been reported after Pfizer-BioNTech COVID-19 vaccination or Moderna COVID-19 vaccination, particularly after the second dose; these were reviewed together and will hereafter be referred to as mRNA COVID-19 vaccination. ACIP has met three times to review the data associated with these reports of serious adverse events and has comprehensively assessed the benefits and risks associated with receipt of these vaccines. ...
- QUOTE: ... In December 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUAs) for Pfizer-BioNTech and Moderna COVID-19 vaccines, and in February 2021, FDA issued an EUA for the Janssen (Johnson & Johnson) COVID-19 vaccine. After each EUA, the Advisory Committee on Immunization Practices (ACIP) issued interim recommendations for vaccine use; currently Pfizer-BioNTech is authorized and recommended for persons aged ≥12 years and Moderna and Janssen for persons aged ≥18 years (1–3). Both Pfizer-BioNTech and Moderna vaccines, administered as 2-dose series, are mRNA-based COVID-19 vaccines, whereas the Janssen COVID-19 vaccine, administered as a single dose, is a recombinant replication-incompetent adenovirus-vector vaccine. ...